Search

Your search keyword '"R. Gentilella"' showing total 22 results

Search Constraints

Start Over You searched for: Author "R. Gentilella" Remove constraint Author: "R. Gentilella" Topic medicine.disease Remove constraint Topic: medicine.disease
Sorry, I don't understand your search. ×
22 results on '"R. Gentilella"'

Search Results

1. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics

2. Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents

Catalog

Books, media, physical & digital resources

3. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics

4. Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care

5. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c

6. Author response for 'Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of Body Mass Index'

7. Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index

8. Personalized intensification of insulin therapy in type 2 diabetes – does a basal–bolus regimen suit all patients?

9. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy

10. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

11. PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS

12. PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE

13. PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS

14. Exenatide: a review from pharmacology to clinical practice

15. Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents

16. Effect of baseline body mass index (BMI; < 30 kg/m2, ≥30-< 35 kg/m2, and ≥35 kg/m2) on glycaemic response and weight change in patients with type 2 diabetes (T2DM) with baseline HbA1c ≥7.5% after treatment with the once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA), dulaglutide, and active comparators in five clinical studies (AWARD 1 – 5)

17. Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

18. Insulin lispro protamine suspension in intensive insulin treatment: an Italian observational study

19. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience

20. Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition

21. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients